Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: Three-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies

    March 2026 in “ American Journal of Clinical Dermatology ”
    Maryanne Senna, Jennifer Soung, Ignasi Gimeno Figueras … Helen Tran
    Studysummary In this study, ritlecitinib 50 mg produced clinically meaningful improvements in scalp hair regrowth over three years for patients aged 12 and older with severe alopecia areata, with 65.1% showing substantial hair regrowth and 31.2% achieving complete regrowth, while also maintaining a consistent safety profile.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 17

    1. Longitudinal Clinical Course, Treatment Outcomes, and Relapse Patterns in Alopecia Areata: A Prospective Cohort Study Frontiers in Medicine · 2025
    2. Patient-Reported Psychosocial Burdens and Quality of Life and Work Productivity Impacts Among Patients With Clinically Distinct Alopecia Areata Severity Profiles Advances in Therapy · 2025
    3. SALT Score Distribution With Ritlecitinib Treatment Up to 24 Months in Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2025
    4. Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents With Alopecia Areata Dermatology and Therapy · 2025
    5. Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme Journal of the European Academy of Dermatology and Venereology · 2025
    6. Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata British Journal of Dermatology · 2024
    7. Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe Dermatology and Therapy · 2024
    8. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    9. Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2 Dermatology and Therapy · 2023
    10. Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials British Journal of Dermatology · 2023
    11. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    12. The Epidemiology of Alopecia Areata: A Population-Based Cohort Study in UK Primary Care British Journal of Dermatology · 2021
    13. A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States Clinical Cosmetic and Investigational Dermatology · 2020
    14. The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials British Journal of Dermatology · 2020
    15. Treatment of Alopecia Areata: An Australian Expert Consensus Statement Australasian journal of dermatology · 2018
    16. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    17. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014